Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unlocking HER2 as a target in KRAS-mutated rectal cancer: a case of significant response to zanidatamab-based regimen.

Frontiers in immunology - 1 Jan 2026

Zhou Kexun, Yang Yu

Abstract excerpt

Background: Colorectal cancer (CRC) with human epidermal growth factor receptor 2 (HER2) overexpression and RAS mutations is often associated with poor response to conventional treatments, presenting substantial therapeutic challenges. This report describes a remarkable response in a patient with HER2-amplified, KRAS-mutated metastatic rectal cancer, who was treated with a zanidatamab-based combination regimen....

Read the complete abstract on PubMed

Topics

Humans
Male
Middle Aged
Rectal Neoplasms
Erb-b2 Receptor Tyrosine Kinases
Proto-Oncogene Proteins p21(ras)
Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Antineoplastic Combined Chemotherapy Protocols

Liver Neoplasms

Adenocarcinoma

Treatment Outcome

Biomarkers, Tumor

Antibodies, Bispecific

Source

Open in PubMed Open full text

Identifiers

PMID: 42688229
DOI: 10.3389/fimmu.2026.1925363
PMCID: PMC13533939

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unlocking HER2 as a target in KRAS-mutated rectal cancer: a case of significant response to zanidatamab-based regimen.PMID 42688229Read ↗

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read ↗

HER2 targeted therapy in colorectal cancer: New horizons.Semantic proximity Read ↗

HER2 activating mutations are targets for colorectal cancer treatment.Semantic proximity Read ↗

Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer.Semantic proximity Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical caseSemantic proximity Read ↗

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.Semantic proximity Read ↗

Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.Semantic proximity Read ↗

The ZEB2‐dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancerSemantic proximity Read ↗

HER2 in Colorectal Carcinoma: Are We There yet?Semantic proximity Read ↗

ERBB2 emerges as a new target for colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.